Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases
Diabetes Metab Syndr. 2025 Jan 7;19(1):103186. doi: 10.1016/j.dsx.2025.103186.
Article
Jan 07, 2024